Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 1

Status

Completed 4Unknown 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6Tumor-Agnostic 5Gastrointestinal 5Breast 5Dermatologic 3Thoracic 2Head & Neck 2Gynecologic 2CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Classical hematology 1

Conditions

Multiple Myeloma 6Anemia 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × reolysin × Plasma cell × Clear all
NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

University of Southern California

Phase 1/2 Active not recruiting
10 enrolled
Plasma cell

Multiple Myeloma

NCT02101944 2024-05-17

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Classical hematologyPlasma cell

Anemia, Multiple Myeloma

NCT03605719 2023-10-06

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Emory University

Phase 1 Completed
23 enrolled
Plasma cell

Multiple Myeloma

NCT02514382 2023-08-14

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

University of Southern California

Phase 1 Completed
14 enrolled
Plasma cell

Multiple Myeloma

NCT03015922 2020-01-22

MUKeleven

University of Leeds

Phase 1 Unknown
4 enrolled
Plasma cell

Multiple Myeloma

NCT01533194 2015-04-15

Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡